Research map: Weight reduction–dependent/–independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH

Back to the article

Papers in this map

  1. Defining Weight‐Loss‐Independent Hepatic Effects of Incretin‐Based Therapies · Mingyuan Zhang · 2026 · Cites this paper
  2. Nucleos(t)ide withdrawal vs Nucleos(t)ide withdrawal with adjuvant pegylated-interferon in HBeAg-negative hepatitis B virus infection (NUC-B Trial) · 2026 · Related
  3. AASLD-EASL Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis · 2026 · Related
  4. Bile acids as the silent harbinger: Early signals of portal hypertension after “successful” Kasai · 2026 · Related
  5. Context-dependent STAT3 signaling in liver fibrosis · 2026 · Related
  6. Buying time: Therapeutic plasma exchange as a bridge to transplant in acute-on-chronic liver failure · 2026 · Related
  7. Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial · 2026 · Related
  8. Two decades of hepatitis E in solid organ transplantation: From endemic insight to unresolved therapeutic questions · 2026 · Related
  9. H4K12 lactylation drives TREM2high macrophages differentiation in liver fibrosis · 2026 · Related
  10. Diabetes, male sex, low levels of HBsAg, HDV RNA, and ALT predict spontaneous HDV suppression in chronic hepatitis D · 2026 · Related
  11. AASLD AST NASPGHAN Practice Guideline on pediatric liver transplantation: Candidate evaluation · 2026 · Related

Source: OpenAlex (CC0)